Roche reports strong 2024 results with 7% (CER) sales growth; fourth quarter marks third straight quarter of 9% growth. In 2024, we advanced healthcare. With bold strategies, innovative diagnostics and medicines and strong financial results, we laid the foundation for a sustainable future — for science, patients, society and our company. We have a clear path ahead: to prevent, stop and cure diseases. Putting patients first, we strive to improve outcomes while lowering costs for patients and healthcare systems worldwide. From hospitals to homes, we’re meeting patients where they need us — improving access and improving lives. With Diagnostics and Pharmaceuticals under one roof, Roche is uniquely positioned to lead the way for better healthcare. Learn more about our 2024 results 👉 https://spkl.io/6047fc0pF Explore more about our journey 👉 https://spkl.io/6048fc0p2
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
We celebrated Chugai Pharmaceutical Co., Ltd. 100th Anniversary earlier this week, which is a remarkable achievement. But beyond recognising and celebrating Chugai’s extraordinary legacy, we want to highlight its R&D culture and capabilities and how their R&D Principles are the pillar of their research-based mentality and pharmaceutical success. Watch the video on YouTube to discover the four principles that define Chugai’s R&D culture. 👉 https://spkl.io/6047fsEUU
-
#Obesity is one of the most expansive health challenges globally and contributes to numerous other diseases. We are very pleased to announce today that we have entered into an exclusive collaboration and licensing agreement with Zealand Pharma to join forces in addressing the significant unmet needs of people living with overweight and obesity #PartneringforInnovation #RochePartnering Read more: https://lnkd.in/dxPyJJq9
-
-
Did you know that women make up just over 30% of the workforce in STEM fields? Scientists like Alice Schlichtiger are breaking these barriers. Imagine diagnostics that are faster, more accurate and personalised. Alice and her team are helping to revolutionise mass spectrometry to transform patient care. Curious about how this innovation will change the future of healthcare? Dive into her inspiring story from our Women in Science series. Read her story: https://lnkd.in/dvH22UMq #massspectrometry #innovation #diagnostics #RocheMassSpec #WomenInScience
-
💪 Real stories. Real change. On International Women’s Day, Roche Australia and Roche Diagnostics Australia celebrated the incredible strength, achievement, and innovative contributions of women in healthcare across 2 #AccelerateAction events. At Roche Australia, we were inspired by Georgie Drury, a women’s health AI and tech pioneer and founder of Metluma whose commitment to turning conversation into action earned her the prestigious Global Garmin Health Award. Georgie showcased how transformative societal change begins with addressing systemic barriers and biases and taking quick action. Our Roche Diagnostics Australia panel, hosted by Smita G. where panelists Tina Kellar, Carmel Caristo, Jade Zhang, CPA and Yu Wooi Ching challenged us to break down barriers and champion the health of all women, no matter their background, age, or circumstances. This panel reminded us that diversity is our strength, and that inclusion is the key to unlocking our potential. #OneRocheAustralia celebrates #IWD2025 and strives to accelerate action for equality for women - every day of the year. 💪🌏 #InternationalWomensDay #GenderEquality #WomenInSTEM #EmpowerWomen #Allyship Brigid Waite, Janelle Keenlyside, Corli Merry, Louise Lindsay, Anna Hornikova, Caroline Ryan, Claire Dowdle, Dominique Hess (Gatto), Elizabeth Moten, Jackie Uglow, Jeannette Le, Kylie McSorley, Laurence Maire, Michelle Tsudama, Melanie Brussolo, Vanessa Cheung, Michelle Tuer, Michelle_Grace Delena, Helen Aunedi, Eleanor Roach, Susan Keyzer, Nhuy Pham, Anthony L., William Vergios, Joseline Ojaimi, Jaimie Yong, Goli Zarshenas, Binh Ta, Erwin Lee
-
-
-
-
-
+2
-
-
Happy Birthday Chugai! Our member company, Chugai Pharmaceutical Co., Ltd., celebrates its 100th anniversary today. For over 20 years, Chugai has been and continues to be a key member of the Roche group, driving innovation forward. Chugai’s aspiration “Innovation beyond imagination” reflects the innovative spirit and unique drug discovery capabilities of the company. We are proud that our unique alliance has enabled patients in Japan to benefit from Roche’s medicines, while Chugai’s innovative products could reach patients worldwide. As Chugai marks its centenary, we look forward to continuing our strong alliance. Roche, together with Chugai, will continue to innovate to build a healthier future for patients around the world for the next 100 years and beyond. Congratulations once again to the entire Chugai team! Learn more about Chugai’s history and the alliance with Roche 👉 https://lnkd.in/d3fxZYqu
-
On World Obesity Day, let's address the overlooked stigma of obesity that hinders access to treatment. At Roche, we embrace a patient-centered approach to fully support the clinical care needs of people living with obesity. #ChangingSystems #WOD2025 #EndWeightStigma Discover more here 👇
-
How is digital health changing cardiovascular and emergency medicine? In the age of digitalization and artificial intelligence, healthcare systems must adapt to cope with the pressure imposed by chronic diseases and increasingly limited available resources. While there is no doubt that these new technologies are part of the answer, the road ahead involving their development, implementation, and adoption by healthcare professionals is far from trivial. In our new video podcast series Cardio Insights hosted by Mathieu Chaffard, leading physicians, researchers, and Roche experts discuss the potential of these solutions and their implications for clinical practice and patient outcomes, in the context of cardiovascular and emergency medicine. The first three episodes are now available, featuring Prof. C. Michael Gibson, M.S., M.D., Prof. Chris Baugh MD, MBA, Prof. Cynthia Papendick, and Prof. Lori Daniels! Tune in to this podcast today on Spotify and YouTube: https://spkl.io/6045fUn4U #CardioInsights #Cardiology #EmergencyMedicine #DigitalHealth
-
At Roche, technology and innovation go hand in hand to transform healthcare. From advanced data analytics to AI-driven diagnostics, cutting-edge software solutions are at the core of modern medical breakthroughs. 💯 Many might not realize it, but behind every precise diagnosis and every breakthrough treatment, technology plays a crucial role. By developing pioneering digital solutions, we are shaping the future of patient care—making treatments more personalized, efficient, and accessible. 🚀 Join us in leveraging technology to drive life-changing innovations in healthcare. ⬇️ Learn more! https://lnkd.in/dbkruURj
-
-
🌍 #TogetherForChange: Transforming Women's Health Roche's XProject is advancing women’s health globally through strategic partnerships, critical initiatives, and tackling gaps in healthcare. Our Changemakers are breaking barriers, championing equitable healthcare, and making a transformative impact on millions of lives. Together, we are raising tough conversations and paving the way for systemic change. 💪❤️ Discover our impact on women’s health in our digital annual report: https://spkl.io/6048flCzk
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang5.000.000.000,00 $
Investor:innen